European Journal of Clinical Pharmacology

, Volume 68, Issue 6, pp 961–968 | Cite as

Population pharmacokinetics of metformin in obese and non-obese patients with type 2 diabetes mellitus

  • Christophe BardinEmail author
  • Estelle Nobecourt
  • Etienne Larger
  • François Chast
  • Jean-Marc Treluyer
  • Saik Urien
Pharmacokinetics and Disposition



The objective of this study was to develop a population pharmacokinetic model and investigate the effect of several demographic covariates on metformin pharmacokinetics in patients with type 2 diabetes mellitus, over a wide range of weights.


A total of 105 patients received different metformin regimens, and pharmacokinetic sampling included a minimum of two concentrations per patient. Plasma determination of metformin was assayed by high performance liquid chromatography. Population pharmacokinetics was modelled using a nonlinear mixed effects model program (Monolix version 3.1 s).


An open one-compartment model adequately described metformin data. Lean body weight was a better size descriptor than actual body weight or ideal body weight for clearance (CL/F) and volume (V/F) parameters. CL/F was negatively related to age and serum creatinine (SCr). The estimation of specific coefficients for these effects gave better results than the use of renal function descriptors (Cockroft or MDRD). A dose effect in the relative bioavailability was demonstrated.


The pharmacokinetics of metformin was influenced by lean body weight on an allometric basis and was related to markers of renal function, age, and serum creatinine in this population of 105 patients.


Metformin Population pharmacokinetics Obese patient Size descriptors Diabetology 


  1. 1.
    Nathan DM, Buse JB, Davidson MB et al (2009) Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 32:193–203PubMedCrossRefGoogle Scholar
  2. 2.
    Hanley MJ, Abernethy DR, Greenblatt DJ (2010) Effect of obesity on the pharmacokinetics of drugs in human. Clin Pharmacokinet 49:71–87PubMedCrossRefGoogle Scholar
  3. 3.
    Cheymol G (2000) Effects of obesity on pharmacokinetics. Clin Pharmacokinet 39:215–231PubMedCrossRefGoogle Scholar
  4. 4.
    Sparreboom A, Wolff AC, Mathijssen RHJ et al (2010) Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol 25:4707–4713CrossRefGoogle Scholar
  5. 5.
    Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL (1997) Efficacy of metformin in type II diabetes: results of a double-blind, placebo controlled, dose response trial. Am J Med 103:491–497PubMedCrossRefGoogle Scholar
  6. 6.
    Graham GG, Punt J, Arora M et al (2011) Clinical pharmacokinetics of metformin. Clin Pharmacokinet 50:81–98PubMedCrossRefGoogle Scholar
  7. 7.
    Devine D (1974) Case study number 25 gentamicin therapy. Drug Intell Clin Pharm 8:650–655Google Scholar
  8. 8.
    Janmahasatian S, Dufull SB, Ash S et al (2005) Quantification of lean bodyweight. Clin Pharmacokinet 44:1051–1065PubMedCrossRefGoogle Scholar
  9. 9.
    Amini H, Ahmadiani A, Gazerani P (2005) Determination of metformin in human plasma by high-performance liquid chromatography. J Chrom B 824:319–322CrossRefGoogle Scholar
  10. 10.
    Kuhn E, Lavielle M (2005) Maximum likelihood estimation in nonlinear mixed effects models. Comput Stat Data Anal 49:1020–1030CrossRefGoogle Scholar
  11. 11.
    R Development Core Team (2009) R: A language and environment for statistical computing. R Foundation for Statistical Computing, ViennaGoogle Scholar
  12. 12.
    McLeay S, Morrish G, Kirkpatrick C et al (2009) Encouraging the move towards predictive population models for the obese using propofol as a motivating example. Pharm Res 26:1626–1634PubMedCrossRefGoogle Scholar
  13. 13.
    Mould D, Holford N, Schellens J et al (2002) Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors. Clin Pharmacol Ther 71:334–348PubMedCrossRefGoogle Scholar
  14. 14.
    Sirtori CR, Franceschini G, Galli-Kienle M et al (1978) Disposition of metformin (N, N-dimethylbiguanide) in man. Clin Pharmacol Ther 24:683–693PubMedGoogle Scholar
  15. 15.
    Pentikaïnen PJ, Neuvonen PJ, Pentillä A (1979) Pharmacokinetics of metformin after intravenous and oral administration to man. Eur J Clin Pharmacol 16:195–202PubMedCrossRefGoogle Scholar
  16. 16.
    Tucker GT, Casey C, Phillips PJ, Connor H, Ward JD, Woods HF (1981) Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol 12:235–246PubMedGoogle Scholar
  17. 17.
    Scheen AJ (1996) Clinical pharmacokinetics of metformin. Clin Pharmacokinet 30:359–371PubMedCrossRefGoogle Scholar
  18. 18.
    Hong Y, Rohatagi S, Habtemariam B, Walker J, Schwartz SL, Mager DE (2008) Population exposure-response modeling of metformin in patients with type 2 diabetes mellitus. J Clin Pharmacol 48:696–707PubMedCrossRefGoogle Scholar
  19. 19.
    Schäfer G (1983) Biguanides: a review of history, pharmacodynamics and therapy. Diab Metab 9:148–163Google Scholar
  20. 20.
    Han PY, Duffull SB, Kirkpatrick CM, Green B (2007) Dosing in obesity: a simple solution to a big problem. Clin Pharmacol Ther 82:505–508PubMedCrossRefGoogle Scholar
  21. 21.
    Erstadt BL (2004) Dosing of medications in morbidly obese patients in intensive care unit setting. Intensive Care Med 30:18–32CrossRefGoogle Scholar
  22. 22.
    Traynor AM, Nafziger AN, Bertino JS (1995) Aminoglycoside dosing weight correction factors for patients of various body sizes. Antimicrob Agents Chemother 39:545–548PubMedGoogle Scholar
  23. 23.
    Green B, Duffull SB (2004) What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol 58:119–133PubMedCrossRefGoogle Scholar
  24. 24.
    Sambol NC, Chiang J, Lin ET et al (1995) Kidney function and age are both predictors of pharmacokinetics of metformin. J Clin Pharmacol 35:1094–1102PubMedGoogle Scholar
  25. 25.
    Lalau JD, Vermersch A, Hary L, Andrejak M, Isnard F, Quichaud J (1990) Type 2 diabetes in the elderly: an assessment of metformin. Int J Clin Pharmacol Ther Toxico 28:329–332Google Scholar
  26. 26.
    Karim A, Slater M, Bradford D et al (2007) Oral antidiabetic drugs: bioavailability assessment of fixed-dose combination tablets of pioglitazone and metformin. Effect of body weight, gender, and race on systematic exposures of each drug. J Clin Pharmacol 47:37–47PubMedCrossRefGoogle Scholar
  27. 27.
    Sambol NC, Brookes LG, Chiang J et al (1996) Food intake and dosage level, but not tablet vs solution dosage form, affect the absorption of metformin HCl in man. Br J Clin Pharmacol 42:510–512PubMedCrossRefGoogle Scholar
  28. 28.
    Tzvetkov MV, Vormfelde SV, Balen B et al (2009) The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2 and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther 86:299–306PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Christophe Bardin
    • 1
    Email author
  • Estelle Nobecourt
    • 2
  • Etienne Larger
    • 2
  • François Chast
    • 1
  • Jean-Marc Treluyer
    • 3
    • 4
  • Saik Urien
    • 3
    • 4
  1. 1.Pharmacy-Pharmacology-Toxicology Department Hôtel-Dieu, AP-HPParis Cédex 04France
  2. 2.Diabetology Department Hôtel-Dieu, AP-HPParisFrance
  3. 3.CIC-0901 Inserm Necker-Cochin, AP-HPParisFrance
  4. 4.EA-3620, Université Paris DescartesParisFrance

Personalised recommendations